In a study of 2267 sporadic amyotrophic lateral sclerosis patients, Ruf et al. report that ∼13% could be genetically resolved with ∼10% being eligible for one of the oncoming gene-specific therapies (SOD1/FUS/C9orf72). This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.